Abstract: The present disclosure relates to stable pharmaceutical compositions comprising fixed dose combination of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of such fixed dose combinations, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

Abstract: Provided herein is a pharmaceutical composition comprising obicetrapib, or a pharmaceutically acceptable salt thereof, and an SGTL2 inhibitor, or a pharmaceutically acceptable salt thereof. Also provided are dosage forms including the same. In some embodiments, the dosage form is a solid dosage form, such as a tablet. Also provided are processes for the preparation of fixed dose formulations of obicetrapib and an SGTL2 inhibitor, and methods for using the same in the treatment of a metabolic disorder (e.g., type 2 diabetes). Also provided are methods of treating or preventing a metabolic disorder in a subject who has or is at risk of developing a metabolic disorder, comprising: administering a therapeutically effective amount of obicetrapib, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of at least one SGLT2 inhibitor, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a pharmaceutical composition and a therapeutic combination comprising obicetrapib and ezetimibe, which may be used in the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia and wherein said subjects are partially or completely intolerant to statins.

Abstract: A new and distinct rose cultivar of the Floribunda class, characterized by: Medium sized yellow flowers that fade to white; borne in many clusters of four to six flowers; very rapid repeat bloom; low bushy plants; stems with few prickles; some fragrance. The cultivar name of this plant is designated as ‘HADICE’. It is being marketed under the commercial name of ‘GOLDEN ICEBERG’.

Abstract: A new and distinct rose cultivar of the Hybrid Tea class characterized by: Having stems without prickles; large yellow flowers slightly pink shaded; flowers borne one to the stem; strong fragrance; rapid repeat bloom; upright bushy plants. The cultivar of this plant is designated as ‘HADQUE’. It is being marketed under the commercial name of ‘SMOOTH QUEEN’.

Abstract: A new and distinct rose cultivar of the Hybrid Tea class characterized by: having stems without prickles; large peach shaded flowers; flowers borne one to the stem; rapid repeat bloom; on upright bushy plants. The generic name of this plant is designated as ‘HADDEL’. It is being mmercial name of ‘SMOOTH DELIGHT’.

Abstract: A new and distinct rose cultivar of the Florabunda class characterized by having long lasting clusters of deep yellow flowers on clean stems without prickles and having a rapid rebloom cycle. The plant is upright and bushy and is of medium height, generally averaging about 1 meter. Stems are well covered with matte foliage. The plant is resistant to mildew, rust and blackspot. The generic name of this plant is designated as ‘HADCUP’. It is being marketed under the commercial name of ‘SMOOTH BUTTERCUP’.